Suchergebnisse - "Melamed, Isaac"

1

Mast cells, brain inflammation and autism

von: Theoharides, Theoharis C.

2016transfer abstract, in: Mexican student-teachers’ “English” language praxicum: Decolonizing attempts

Wird geladen...
2

Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Human Immunoglobulin 16.5% Administered at Modified Dosing Regimens in Patients with Primary Immunodeficiency Diseases – Study Design

von: Melamed, Isaac

2020, in: The journal of allergy and clinical immunology

Wird geladen...
3

Subcutaneous Immunoglobulin 16.5% (Cutaquig) in Primary Immunodeficiency Disease: Safety, Efficacy, and Patient Satisfaction with Modified Dosing Regimens

von: Gupta, Sudhir

2023, in: Clinical immunology

Wird geladen...
4

Analyses of a Subset of Patients with Primary Immunodeficiency Diseases (PIDD) Who Switched Modes of Administration of Immunoglobulin (Ig) Therapy during Three Consecutive Studies

von: Wasserman, Richard L.

2017, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
5

Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”

von: Suez, Daniel

2017, in: Journal of clinical immunology

Wird geladen...
6

Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North America

von: Suez, Daniel

2016, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
7

Observational Study to Determine the Tolerability of Intravenous Immunoglobulin 5% for the Treatment of Patients Diagnosed with Primary Immunodeficiency Disorders

von: Reuven Melamed, Isaac

2018, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
8

Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies

von: Stein, Mark R.

2016, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
9

Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study

von: Melamed, Isaac R.

2018transfer abstract, in: The face of wrongdoing? An expectancy violations perspective on CEO facial characteristics and media coverage of misconducting firms

Wird geladen...
10

Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (rHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs)

von: Melamed, Isaac Reuven

2014, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
11

Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America

von: Suez, Daniel

2016, in: Journal of clinical immunology

Wird geladen...
12

Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens

von: Gupta, Sudhir

2023, in: Journal of clinical immunology

Wird geladen...
13

Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI)

von: Wasserman, Richard L.

2015, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
14

BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children

von: Kriván, Gergely

2022, in: Journal of clinical immunology

Wird geladen...
15

Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study

von: Borte, Michael

2017, in: Journal of clinical immunology

Wird geladen...
16

Long-Term Safety, Efficacy, and Tolerability of Subcutaneous Human Immunoglobulin 16.5% in Patients with Primary Immunodeficiencies

von: Gupta, Sudhir

2021, in: Antidiabetic treatment in elderly patients with low performance status admitted to internal medicine ward

Wird geladen...
17

Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease

von: Wasserman, Richard L.

2016, in: Journal of clinical immunology

Wird geladen...
18

Evaluation of the Safety, Tolerability, and Pharmacokinetics of $ Gammaplex^{®} $ 10% Versus $ Gammaplex^{®} $ 5% in Subjects with Primary Immunodeficiency

von: Wasserman, Richard L.

2017, in: Journal of clinical immunology

Wird geladen...
19

Carimune NF Liquid is a Safe and Effective Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency Diseases

von: Berger, Melvin

2007, in: Journal of clinical immunology

Wird geladen...
20

Subcutaneous Immunoglobulin 16.5% (Cutaquig) is Safe and Efficacious at Modified Dosing Regimens in Patients With Primary Immunodeficiency Disease

von: Gupta, Sudhir

2022, in: The journal of allergy and clinical immunology

Wird geladen...

Nicht das Richtige dabei?

Schreiben Sie uns!